Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) EBITDA: 2010-2018

Historic EBITDA for EyePoint Pharmaceuticals (EYPT) over the last 9 years, with Jun 2018 value amounting to -$53.2 million.

  • EyePoint Pharmaceuticals' EBITDA fell 454.04% to -$33.1 million in Q3 2018 from the same period last year, while for Sep 2018 it was -$80.3 million, marking a year-over-year decrease of 364.05%. This contributed to the annual value of -$53.2 million for FY2018, which is 187.32% down from last year.
  • Per EyePoint Pharmaceuticals' latest filing, its EBITDA stood at -$53.2 million for FY2018, which was down 187.32% from -$18.5 million recorded in FY2017.
  • In the past 5 years, EyePoint Pharmaceuticals' EBITDA ranged from a high of $6.2 million in FY2015 and a low of -$53.2 million during FY2018.
  • Moreover, its 3-year median value for EBITDA was -$21.6 million (2016), whereas its average is -$31.1 million.
  • In the last 5 years, EyePoint Pharmaceuticals' EBITDA spiked by 147.22% in 2015 and then slumped by 446.35% in 2016.
  • Over the past 5 years, EyePoint Pharmaceuticals' EBITDA (Yearly) stood at -$13.2 million in 2014, then soared by 147.22% to $6.2 million in 2015, then tumbled by 446.35% to -$21.6 million in 2016, then climbed by 14.49% to -$18.5 million in 2017, then tumbled by 187.32% to -$53.2 million in 2018.